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EDITORIAL
Metabolic syndrome  and peripheral  arterial  disease
Síndrome  metabólico  y enfermedad  arterial  periférica
The  metabolic  syndrome  (MetS)  is  a constellation  of
metabolic  risk  factors  closely  linked  to  insulin  resistance.1
At  present,  various  definitions  for  MetS  are  used.  Accord-
ing  to  the  criteria  described  by  of  the  Adults  Treatment
Panel  III  recently  revised  by the American  Heart  Asso-
ciation/National  Heart,  Lung, and Blood  Institute  (rATP
III-MetS)2 the  MetS  is  defined  as  an  alteration  in three  or
more  of  the following  features:  abdominal  obesity  (waist
circumference  >102  cm in men;  >88  cm  in women),  ele-
vated  blood  pressure  (>130  mmHg  systolic  or  >85 mmHg
diastolic,  and/or  use  of antihypertensive  agents),  hyper-
triglyceridemia  (>150  mg/dL),  low  levels  of  serum  HDLc
(<40  mg/dL  in men,  <50 mg/dL  in women),  and high  fas-
ting  glucose  (>100  mg/dL,  and/or  use  of  glucose-lowering
agents).  Using  International  Diabetes  Federation  (IDF)
criteria,3 MetS  was  diagnosed  in  patients  who  had  a waist
circumference  >94  cm in  men  and  >80  cm  in women,  plus
two  or more  of  the following:  elevated  blood  pressure,
hypertriglyceridemia,  low HDLc  levels,  and  high  fasting
glucose,  each  defined  by  the same  criteria  used  for the
rATP  III  definition.  Diabetes  mellitus  was  defined  as  fas-
ting  plasma  glucose  >126  mg/dL  or  use  of  glucose-lowering
agents.  MetS  is  a very  common  clinical  condition  in  West-
ern  countries:  in the last  decade,  the  prevalence  of  MetS
has  increased  in the United  States4 and elsewhere.  In peo-
ple  >20  years  old  it  is  24%  and  it rises  to  >40%  in patients
≥60  years  of  age.5 Several  studies  evaluated  the  presence
of  the  Mets  in  different  populations.  However,  the use  of
different  diagnostic  criteria  for  the  Mets  is,  at least  in
part,  the  reasons  for  differences  in prevalence  rate,  hin-
dering  meaningful  comparisons  between  populations.6,7 In
a  study  by  Trevisan  et al.,  in patients  aged  50  years  or
above,  women  showed  a  higher  prevalence  than men,8
although  the  prevalence  of the Mets  was  not  influenced  by
age.  The  pathogenesis  of the syndrome  has  multiple  ori-
gins,  but  obesity  and  sedentary  lifestyle  coupled  with  diet
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and  still  largely  unknown  genetic  factors  clearly  interact
and  may  determine  the syndrome.9 The  combination  of
risk  factors  comprising  the Mets  interacts  synergistically
causing  or  accelerating  the progression  of  atherosclerosis.1
Several  clinical  studies  recognized  MetS  as  a cause  respon-
sible  for the  endothelial  dysfunction,  which  represents  the
first  ‘‘step’’  in  atherothrombotic  disease  and,  in addition,
observed  an association  between  increased  carotid  intima-
media  thickness  (IMT)  and  MetS.10,11 Therefore,  patients
with  Mets  have a higher  risk  of  developing  cardiovascular
morbidity  and  mortality  than  subjects  without  the syndrome
(12.0%  versus  2.2%):  a  two-  to  three-fold  increased  risk  of
coronary  heart  disease  (CHD)  and  stroke  and cardiovascular
mortality  has  been  reported  in  literature.1,6,8,12 A prospec-
tive  study  published  by  Novo et  al.  showed that in the
subgroup  of  patients  with  MetS,  the prevalence  of subclinical
atherosclerosis,  defined  as  increased  IMT  (common  carotid
IMT > 0.90  mm)  with  or  without  atherosclerotic  plaque,  was
significantly  higher  than  in  participants  without  MetS  and
defined  this  Syndrome  as  a  CV risk  factor:  participants  with
MetS  had  a significantly  higher  prevalence  of vascular  dis-
ease  in a 20-  year  follow-up  (49%)  than  participants  without
MetS  (29%)  (p  < 0.01).9,13 Conversely,  little  is  known  about
the  predictive  role  of  MetS  in  peripheral  arterial  disease
(PAD),  which  affecting  about  27  million  people  in Europe  and
the  United  States.  Brevetti  et  al.  found  that  more  than  50%
of  PAD  patients  met the  criteria  for  rATP  III-MetS.  Neverthe-
less,  the results  show  that  IDF-MEtS,  but  not rATPIII-MetS,
is  an independent  predictor  of cardiovascular  events.14 In a
study  by  Gorter  et  al.  has  emerged  that  the metabolic  syn-
drome,  according  to the  ATP III  criteria,  is  highly  prevalent
in  patients  with  a  recent  diagnose  of a clinical  manifestation
of  atherosclerosis  (46%),  especially  in PAD  patients  (58%).15
A  more  recent study  revealed  that patients  with  occlusive
or  aneurysmatic  PAD  have  a  high  prevalence  of  metabolic
syndrome  and  that  in  both  groups  of  patients  the presence
of  metabolic  syndrome  was  independently  associated  with
an  increased  risk  for the occurrence  of  CV events  during
long-term  follow-up  but  no with  an incremental  risk  for  CV
mortality.16 The  Mets  is  a common  comorbidity  in  claudicants
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and  must  be  actively  searched  because  the early  diagno-
sis  and  treatment  of  MetS  may  influence  PAD  progression.17
There  are few  studies  in  literature  which  evaluated  the
association  between  MetS  and  PAD.  These  studies  demon-
strated  that  the prevalence  of  MetS  is  higher  in patients  with
PAD  but  their  limits  were  that  the patients  often  exhibited
clinical  manifestations  of  arteriosclerosis  in other  vascular
territories.14--17 In  this  regard  the  objective  of  the study  pre-
sented  in this  issue  of Rev  Clin  Esp  by Estirado  et  al.18 is
to  assess  the prevalence  of  MetS  in  patients  with  PAD  but
without  known  atherosclerosis  in other  districts.  The  authors
demonstrated  that the prevalence  of  MetS  in  PAD  patients
is  high  (63%)  and  is  independent  of the evolution  time  of
PAD.  According  to  our  experience  we are  agree  with  Esti-
rado  et  al.18;  we  believe  that PAD  (documented  using  ABI
<0.9,  lower  limb  amputation  due  to  chronic  ischemia  or  prior
revascularization  in the  lower  limbs),  can  be  presented  in
MetS  patients  and that  it is  a validated  marker  of  subcli-
nical  atherosclerosis  and  a predictor  of  CV  events,  like an
increased  carotid  IMT.
Considering  the close  association  between  MetS  and
GCVR  (global  cardiovascular  risk),  it is  relevant  to  screen
already  high-risk  patients  for  the  MetS. Instead  of treating
individual  components  of the metabolic  syndrome,  treating
the  underlying  pathophysiological  disturbance  (for instance,
insulin  resistance)  would  ideally  be  the  therapeutic  option  of
first  choice.15 It  is  also  recommend  preventing  the develop-
ment  of  MetS  abnormalities  (for  example  with  daily  physical
activity,  Mediterranean  diet  and  early  started pharmacolog-
ical  treatment  of modifiable  risk  factors,  as  suggested  by
many  studies)19,20 and  investigating  the presence  of  sub-
clinical  atherosclerosis  in all patients  over  45  years,  by
ultrasound  test,  because  in primary  prevention,  the IMT
measurement  can  give  further  information  for  a  better  strat-
ification  of  GCVR.21
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